Go Pro
→ SpaceX pays a 10X launch penalty (From Freedom Financial) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Alkermes plc stock logo
ALKS
Alkermes
$45.40
-0.2%		$50.17
$26.40
▼
$55.67
$7.63B0.311.22 million shs1.40 million shs
Hemab Therapeutics Holdings, Inc. stock logo
COAG
Hemab Therapeutics
$44.50
-0.2%		$45.78
$23.00
▼
$55.42
$2.08BN/A300,465 shs429,283 shs
Immunovant, Inc. stock logo
IMVT
Immunovant
$38.75
-2.1%		$40.49
$14.58
▼
$45.42
$8.17B0.811.15 million shs1.02 million shs
Spyre Therapeutics, Inc. stock logo
SYRE
Spyre Therapeutics
$86.93
-4.3%		$98.03
$14.51
▼
$110.18
$7.98B2.991.08 million shs1.01 million shs
The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout Cover
The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Alkermes plc stock logo
ALKS
Alkermes
-0.20%-4.86%-8.10%+1.07%+63.02%
Hemab Therapeutics Holdings, Inc. stock logo
COAG
Hemab Therapeutics
-0.16%-0.45%-10.77%+65.18%+4,449,999,900.00%
Immunovant, Inc. stock logo
IMVT
Immunovant
-2.07%-1.87%-2.86%+17.85%+136.28%
Spyre Therapeutics, Inc. stock logo
SYRE
Spyre Therapeutics
-4.25%-0.14%-17.47%+7.63%+419.30%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Alkermes plc stock logo
ALKS
Alkermes
$45.40
-0.2%		$50.17
$26.40
▼
$55.67
$7.63B0.311.22 million shs1.40 million shs
Hemab Therapeutics Holdings, Inc. stock logo
COAG
Hemab Therapeutics
$44.50
-0.2%		$45.78
$23.00
▼
$55.42
$2.08BN/A300,465 shs429,283 shs
Immunovant, Inc. stock logo
IMVT
Immunovant
$38.75
-2.1%		$40.49
$14.58
▼
$45.42
$8.17B0.811.15 million shs1.02 million shs
Spyre Therapeutics, Inc. stock logo
SYRE
Spyre Therapeutics
$86.93
-4.3%		$98.03
$14.51
▼
$110.18
$7.98B2.991.08 million shs1.01 million shs
The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout Cover
The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Alkermes plc stock logo
ALKS
Alkermes
-0.20%-4.86%-8.10%+1.07%+63.02%
Hemab Therapeutics Holdings, Inc. stock logo
COAG
Hemab Therapeutics
-0.16%-0.45%-10.77%+65.18%+4,449,999,900.00%
Immunovant, Inc. stock logo
IMVT
Immunovant
-2.07%-1.87%-2.86%+17.85%+136.28%
Spyre Therapeutics, Inc. stock logo
SYRE
Spyre Therapeutics
-4.25%-0.14%-17.47%+7.63%+419.30%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Alkermes plc stock logo
ALKS
Alkermes
2.72
Moderate Buy$54.5620.18% Upside
Hemab Therapeutics Holdings, Inc. stock logo
COAG
Hemab Therapeutics
2.57
Moderate Buy$51.4015.51% Upside
Immunovant, Inc. stock logo
IMVT
Immunovant
2.55
Moderate Buy$44.0013.55% Upside
Spyre Therapeutics, Inc. stock logo
SYRE
Spyre Therapeutics
2.87
Moderate Buy$109.6926.18% Upside

Current Analyst Ratings Breakdown

Latest COAG, IMVT, SYRE, and ALKS Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
9/9/2026
Spyre Therapeutics, Inc. stock logo
SYRE
Spyre Therapeutics
Wedbush logo
Wedbush
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingOutperform$123.00
9/8/2026
Spyre Therapeutics, Inc. stock logo
SYRE
Spyre Therapeutics
BTIG Research logo
BTIG Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$121.00
9/1/2026
Spyre Therapeutics, Inc. stock logo
SYRE
Spyre Therapeutics
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D-)
8/26/2026
Spyre Therapeutics, Inc. stock logo
SYRE
Spyre Therapeutics
Deutsche Bank Aktiengesellschaft logo
Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetBuy$135.00 ➝ $127.00
8/26/2026
Spyre Therapeutics, Inc. stock logo
SYRE
Spyre Therapeutics
Wedbush logo
Wedbush
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetOutperform$130.00 ➝ $123.00
8/26/2026
Spyre Therapeutics, Inc. stock logo
SYRE
Spyre Therapeutics
BTIG Research logo
BTIG Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetBuy$132.00 ➝ $121.00
8/25/2026
Immunovant, Inc. stock logo
IMVT
Immunovant
Cantor Fitzgerald logo
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingOverweight
8/13/2026
Hemab Therapeutics Holdings, Inc. stock logo
COAG
Hemab Therapeutics
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageSell (D+)
8/12/2026
Hemab Therapeutics Holdings, Inc. stock logo
COAG
Hemab Therapeutics
Wedbush logo
Wedbush
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOutperform$55.00 ➝ $64.00
8/11/2026
Hemab Therapeutics Holdings, Inc. stock logo
COAG
Hemab Therapeutics
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$52.00 ➝ $60.00
8/11/2026
Spyre Therapeutics, Inc. stock logo
SYRE
Spyre Therapeutics
BTIG Research logo
BTIG Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$112.00 ➝ $132.00
(Data available from 9/10/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Alkermes plc stock logo
ALKS
Alkermes
$1.48B5.16$1.67 per share27.17$11.02 per share4.12
Hemab Therapeutics Holdings, Inc. stock logo
COAG
Hemab Therapeutics
N/AN/AN/AN/AN/AN/A
Immunovant, Inc. stock logo
IMVT
Immunovant
N/AN/AN/AN/A$4.19 per shareN/A
Spyre Therapeutics, Inc. stock logo
SYRE
Spyre Therapeutics
$890K8,589.47N/AN/A$7.21 per share12.06
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Alkermes plc stock logo
ALKS
Alkermes
$241.66M$0.38119.48189.17N/A3.96%4.15%2.19%10/28/2026 (Estimated)
Hemab Therapeutics Holdings, Inc. stock logo
COAG
Hemab Therapeutics
N/A-$24.78N/AN/AN/AN/AN/AN/AN/A
Immunovant, Inc. stock logo
IMVT
Immunovant
-$505.61M-$2.82N/AN/AN/AN/A-69.59%-62.49%11/9/2026 (Estimated)
Spyre Therapeutics, Inc. stock logo
SYRE
Spyre Therapeutics
-$155.20M-$1.95N/AN/AN/AN/A-30.74%-22.23%11/3/2026 (Estimated)

Latest COAG, IMVT, SYRE, and ALKS Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/11/2026Q2 2026
Hemab Therapeutics Holdings, Inc. stock logo
COAG
Hemab Therapeutics
-$0.63-$0.80-$0.17-$0.80N/AN/A
8/6/2026Q1 2027
Immunovant, Inc. stock logo
IMVT
Immunovant
-$0.6289-$0.75-$0.1211-$0.75$7.10 million$7.10 million
8/4/2026Q2 2026
Spyre Therapeutics, Inc. stock logo
SYRE
Spyre Therapeutics
-$0.7589-$0.36+$0.3989-$0.36N/AN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Alkermes plc stock logo
ALKS
Alkermes
N/AN/AN/AN/AN/A
Hemab Therapeutics Holdings, Inc. stock logo
COAG
Hemab Therapeutics
N/AN/AN/AN/AN/A
Immunovant, Inc. stock logo
IMVT
Immunovant
N/AN/AN/AN/AN/A
Spyre Therapeutics, Inc. stock logo
SYRE
Spyre Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Alkermes plc stock logo
ALKS
Alkermes
0.82
2.30
1.85
Hemab Therapeutics Holdings, Inc. stock logo
COAG
Hemab Therapeutics
N/A
35.85
35.85
Immunovant, Inc. stock logo
IMVT
Immunovant
N/A
7.27
7.27
Spyre Therapeutics, Inc. stock logo
SYRE
Spyre Therapeutics
N/A
18.53
18.53

Institutional Ownership

CompanyInstitutional Ownership
Alkermes plc stock logo
ALKS
Alkermes
95.21%
Hemab Therapeutics Holdings, Inc. stock logo
COAG
Hemab Therapeutics
N/A
Immunovant, Inc. stock logo
IMVT
Immunovant
47.08%
Spyre Therapeutics, Inc. stock logo
SYRE
Spyre Therapeutics
80.39%

Insider Ownership

CompanyInsider Ownership
Alkermes plc stock logo
ALKS
Alkermes
4.59%
Hemab Therapeutics Holdings, Inc. stock logo
COAG
Hemab Therapeutics
N/A
Immunovant, Inc. stock logo
IMVT
Immunovant
1.90%
Spyre Therapeutics, Inc. stock logo
SYRE
Spyre Therapeutics
15.69%
CompanyEmployeesShares OutstandingFree FloatOptionable
Alkermes plc stock logo
ALKS
Alkermes
2,050167.76 million160.06 millionOptionable
Hemab Therapeutics Holdings, Inc. stock logo
COAG
Hemab Therapeutics
7246.71 millionN/AN/A
Immunovant, Inc. stock logo
IMVT
Immunovant
120206.55 million202.63 millionOptionable
Spyre Therapeutics, Inc. stock logo
SYRE
Spyre Therapeutics
7387.94 million74.14 millionOptionable

Recent News About These Companies

Squarepoint Ops LLC Invests $12.39 Million in Spyre Therapeutics, Inc. $SYRE
 |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-squarepoint-ops-llc-invests-1239-million-in-spyre-therapeutics-inc-syre-2026-09-10/
Allianz Asset Management GmbH Takes Position in Spyre Therapeutics, Inc. $SYRE
September 10 at 3:03 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-allianz-asset-management-gmbh-takes-position-in-spyre-therapeutics-inc-syre-2026-09-10/
Spyre Therapeutics (NASDAQ:SYRE) Earns Buy Rating from BTIG Research
September 10 at 1:24 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31013710
Spyre Therapeutics, Inc. (SYRE) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript
September 9 at 3:00 PM  |  seekingalpha.comhttps://seekingalpha.com/article/4944572-spyre-therapeutics-inc-syre-presents-at-citigroups-biopharma-back-to-school-summit-2026
Spyre Therapeutics (SYRE) Stock Surges as Guggenheim Declares It Top Biotech Following UC Trial Results
September 9 at 1:58 PM  |  blockonomi.comhttps://blockonomi.com/spyre-therapeutics-syre-stock-surges-as-guggenheim-declares-it-top-biotech-following-uc-trial-results/
Spyre's Anti-IL-23 Antibody Meets Goal in Ulcerative Colitis Study
September 9 at 11:01 AM  |  zacks.comhttps://www.zacks.com/stock/news/2987021/spyre-s-anti-il-23-antibody-meets-goal-in-ulcerative-colitis-study?cid=cs-stocknewsapi-ft-analyst_blog|company_news_medical_sector-2987021
Wedbush Reiterates "Outperform" Rating for Spyre Therapeutics (NASDAQ:SYRE)
September 9 at 8:29 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/analyst-wedbush-reiterates-outperform-rating-for-spyre-therapeutics-nasdaq-syre-2026-09-09/
Maven Securities LTD Invests $3.55 Million in Spyre Therapeutics, Inc. $SYRE
September 9 at 5:51 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-maven-securities-ltd-invests-355-million-in-spyre-therapeutics-inc-syre-2026-09-09/
Spyre Announces Potential Best-in-Class SPY003 (anti-IL-23) Part A Induction Results from SKYLINE Trial, Completing Proof-of-Concept for All Three Components of its IBD ...
September 8 at 12:55 PM  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/spyre-announces-potential-best-in-class-spy003-anti-il-23-part-a-induction-results-from-skyline-trial-completing-proof-of-concept-for-all-three-components-of-its-ibd-combinations-1036528172
Spyre Therapeutics Reports Positive Phase 2 SPY003 Data In Ulcerative Colitis
September 8 at 12:55 PM  |  rttnews.comhttps://www.rttnews.com/3689162/spyre-therapeutics-reports-positive-phase-2-spy003-data-in-ulcerative-colitis.aspx
Spyre Therapeutics' SPY003 Meets Phase 2 Primary Endpoint in Ulcerative Colitis
September 8 at 12:55 PM  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/spyre-therapeutics-apos-spy003-meets-133515544.html
Spyre Therapeutics' (SYRE) Buy Rating Reiterated at BTIG Research
September 8 at 11:41 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/analyst-spyre-therapeutics-syre-buy-rating-reiterated-at-btig-research-2026-09-08/
Spyre Therapeutics (NASDAQ:SYRE) Shares Gap Down - Here's What Happened
September 8 at 11:19 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/price-spyre-therapeutics-nasdaq-syre-shares-gap-down-heres-what-happened-2026-09-08/
Spyre Announces Potential Best-in-Class SPY003 (anti-IL-23) Part A Induction Results from SKYLINE Trial, Completing Proof-of-Concept for All Three Components of its IBD Combinations
September 8 at 8:00 AM  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/09/08/3357613/0/en/spyre-announces-potential-best-in-class-spy003-anti-il-23-part-a-induction-results-from-skyline-trial-completing-proof-of-concept-for-all-three-components-of-its-ibd-combinations.html
Spyre Therapeutics Announces Grants of Inducement Awards
September 4, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/09/04/3356774/0/en/spyre-therapeutics-announces-grants-of-inducement-awards.html
Spyre Therapeutics (NASDAQ:SYRE) Insider Heidy King-Jones Sells 400 Shares of Stock
September 4, 2026  |  insidertrades.comhttps://www.insidertrades.com/alerts/nasdaq-syre-insider-buying-and-selling-2026-09-04/
Insider Selling: Spyre Therapeutics (NASDAQ:SYRE) Insider Sells $36,000.00 in Stock
September 3, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/insider-insider-selling-spyre-therapeutics-nasdaq-syre-insider-sells-3600000-in-stock-2026-09-03/
Spyre Therapeutics (NASDAQ:SYRE) CFO Scott Burrows Sells 7,500 Shares
September 3, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/insider-spyre-therapeutics-nasdaq-syre-cfo-scott-burrows-sells-7500-shares-2026-09-03/
Insider Selling: Spyre Therapeutics (NASDAQ:SYRE) CEO Sells 15,000 Shares of Stock
September 3, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/insider-insider-selling-spyre-therapeutics-nasdaq-syre-ceo-sells-15000-shares-of-stock-2026-09-03/
Spyre Therapeutics (NASDAQ:SYRE) CFO Sells 18,232 Shares of Stock
September 3, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/insider-spyre-therapeutics-nasdaq-syre-cfo-sells-18232-shares-of-stock-2026-09-03/
Heidy King-Jones Sells 27,999 Shares of Spyre Therapeutics (NASDAQ:SYRE) Stock
September 3, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/insider-heidy-king-jones-sells-27999-shares-of-spyre-therapeutics-nasdaq-syre-stock-2026-09-03/

New MarketBeat Followers Over Time

Media Sentiment Over Time

Alkermes stock logo

Alkermes NASDAQ:ALKS

$45.40 -0.09 (-0.20%)
Closing price 09/9/2026 04:00 PM Eastern
Extended Trading
$45.42 +0.02 (+0.03%)
As of 09:11 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; and LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.

Hemab Therapeutics stock logo

Hemab Therapeutics NASDAQ:COAG

$44.50 -0.07 (-0.16%)
As of 09/9/2026 04:00 PM Eastern

We are a clinical-stage biotechnology company developing therapies that reimagine the treatment of blood coagulation disorders to sustain life and human resilience. Our mission is to build the leading coagulation company by discovering, developing, and commercializing innovative therapies for the millions of patients worldwide suffering from serious bleeding and thrombotic diseases. Coagulation disorders encompass a broad and heterogeneous group of conditions, and many patients experience significant life-long disease burden due to either a lack of available prophylactic therapies or limitations associated with existing treatment approaches. Our lead asset, sutacimig (HMB-001), is a bispecific antibody currently in Phase 1/2 clinical development for the prophylactic treatment of Glanzmann thrombasthenia and Phase 2 clinical development for the prophylactic treatment of Factor VII deficiency. Our second clinical-stage asset, HMB-002, is a monovalent antibody in Phase 1/2 clinical development for the subcutaneous prophylactic treatment of Von Willebrand Disease. We are also advancing multiple preclinical and discovery-stage assets. We estimate that there are approximately an aggregate of 10,000 patients with Glanzmann thrombasthenia and Factor VII deficiency and an aggregate of 120,000 patients with Von Willebrand Disease in the geographies where we intend to commercialize our assets, including the United States, the European Union, Japan, the Gulf Cooperation Council countries and other select regions. With greater disease burden awareness, potential regulatory approvals of new prophylactic options and expanding global reach of these options, we believe the overall number of addressable patients for our clinical-stage assets, and preclinical and discovery stage programs could be greater than we currently estimate. We aim to establish the industry’s leading coagulation franchise through the execution of our “Hemab 2x3 by 2030” strategic roadmap, which is designed to build a franchise consisting of 2 commercial medicines, 2 new late-stage clinical programs, and 2 new early-stage clinical programs by 2030. We have not yet initiated pivotal trials for any of our product candidates, and due to the novel and unproven nature of our programs, their current stage of development and the lack of approved prophylactic therapies to inform endpoint selection and trial design, we may not be able to achieve our strategic goals on the timeline we expect or at all. Our principal executive offices are located in Cambridge, MA.

Immunovant stock logo

Immunovant NASDAQ:IMVT

$38.75 -0.82 (-2.07%)
Closing price 09/9/2026 04:00 PM Eastern
Extended Trading
$38.42 -0.33 (-0.86%)
As of 09:19 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that target the neonatal fragment crystallizable receptor for the treatment of myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, and Graves diseases, as well as warm autoimmune hemolytic anemia. The company is headquartered in New York, New York. Immunovant, Inc. operates as a subsidiary of Roivant Sciences Ltd.

Spyre Therapeutics stock logo

Spyre Therapeutics NASDAQ:SYRE

$86.93 -3.86 (-4.25%)
Closing price 09/9/2026 04:00 PM Eastern
Extended Trading
$88.28 +1.35 (+1.56%)
As of 09:20 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Spyre Therapeutics, Inc., a preclinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD). It develops SPY001, a human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease). The company is also developing SPY002, a human monoclonal antibody (mAb)candidates designed to bind to tumor necrosis factor-like ligand 1A; and SPY120, a combination of SPY001 (anti-a4ß7) and SPY002 (anti-TL1A) antibodies, which are in preclinical studies. In addition, its other early-stage programs include SPY003, an anti-IL-23 mAb; SPY004, a novel mechanism of action (MOA) mAb; SPY130, a combination of anti-a4ß7 and anti-IL-23 mAbs; and SPY230, a combination of anti-TL1A and anti-IL-23 mAbs. The company was formerly known as Aeglea BioTherapeutics, Inc. and changed its name to Spyre Therapeutics, Inc. in November 2023. Spyre Therapeutics, Inc. was incorporated in 2013 and is based in Waltham, Massachusetts.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas